基于三联的产前外显子组测序结合剪接位点与线粒体基因组评估在胎儿超声异常妊娠中的应用价值:前瞻性队列研究
这项前瞻性单中心研究纳入90例超声异常且CNV-seq结果正常的持续妊娠,行基于三联的产前外显子组测序(覆盖外显子编码区、剪接区及线粒体基因组)。28例(31.1%)获得可解释超声异常的诊断结果,脑异常诊断率最高(3/6,50.0%),其次为水肿(4/9,44.4%)和骨骼异常(13/34,38.2%);7例(7.8%)检出胎儿或父母偶然发现。作者认为基于三联的产前外显子组测序可提供额外遗传信息,但需谨慎遗传咨询。
要点
- 超声异常且CNV-seq正常时,基于三联的产前外显子组测序总体诊断率为31.1%(28/90)。
- 脑异常诊断率最高(3/6,50.0%),其次为水肿(4/9,44.4%)和骨骼异常(13/34,38.2%)。
- 7例(7.8%)检出胎儿或父母偶然发现,包括神经发育障碍相关基因及线粒体基因变异。
核心结论
- 基于三联的产前外显子组测序可为CNV-seq未诊断的胎儿超声异常妊娠提供额外遗传信息,其报告的偶然发现和父母携带者状态扩展了临床应用,但需谨慎遗传咨询。
研究设计与样本
- 前瞻性队列研究,纳入2020年9月至2021年11月中国单中心90例超声异常且CNV-seq结果正常的持续妊娠,行基于三联的产前外显子组测序,panel覆盖外显子编码区、剪接区及线粒体基因组,检测胎儿及父母。
诊断标准与关键数值
- 总体诊断率31.1%(28/90),即检出可解释胎儿超声异常的诊断结果。
- 脑异常诊断率50.0%(3/6),水肿44.4%(4/9),骨骼异常38.2%(13/34)。
- 28例诊断病例共检出20个基因的34个变异,其中55.9%(19/34)为新发变异。
- 6例(6.7%)检出与胎儿表型相关的意义不明变异(VUS)。
- 7例(7.8%)检出胎儿(n=4)或父母(n=3)偶然发现。
临床应用与阅片要点
- 诊断结果或胎儿偶然发现促使26个家庭(26/72,36.1%)做出终止妊娠决定。
- 阴性pES结果或检出VUS促使40个家庭(40/72,55.6%)继续妊娠,最终均活产。
- 作者认为基于三联的产前外显子组测序可提供额外遗传信息,但需谨慎遗传咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the utility of trio-based prenatal exome sequencing (pES), incorporating splice-site and mitochondrial genome assessment, in the prenatal diagnosis of fetuses with ultrasound anomalies and normal copy-number variant sequencing (CNV-seq) results.
METHODS: This was a prospective study of 90 ongoing pregnancies with ultrasound anomalies that underwent trio-based pES after receiving normal CNV-seq results, from September 2020 to November 2021, in a single center in China. By using pES with a panel encompassing exome coding and splicing regions as well as mitochondrial genome for fetuses and parents, we identified the underlying genetic causes of fetal anomalies, incidental fetal findings and parental carrier status. Information on pregnancy outcome and the impact of pES findings on parental decision-making was collected.
RESULTS: Of the 90 pregnancies included, 28 (31.1%) received a diagnostic result that could explain the fetal ultrasound anomalies. The highest diagnostic yield was noted for brain abnormalities (3/6 (50.0%)), followed by hydrops (4/9 (44.4%)) and skeletal abnormalities (13/34 (38.2%)). Collectively, 34 variants of 20 genes were detected in the 28 diagnosed cases, with 55.9% (19/34) occurring de novo. Variants of uncertain significance (VUS) associated with fetal phenotypes were detected in six (6.7%) fetuses. Interestingly, fetal (n = 4) and parental (n = 3) incidental findings (IFs) were detected in seven (7.8%) cases. These included two fetuses carrying a de-novo likely pathogenic (LP) variant of the CIC and FBXO11 genes, respectively, associated with neurodevelopmental disorders, and one fetus with a LP variant in a mitochondrial gene. The remaining fetus presented with unilateral renal dysplasia and was incidentally found to carry a pathogenic PKD1 gene variant resulting in adult-onset polycystic kidney, which was later confirmed to be inherited from the mother. In addition, parental heterozygous variants associated with autosomal recessive diseases were detected in three families, including one with additional fetal diagnostic findings. Diagnostic results or fetal IFs contributed to parental decision-making about termination of the pregnancy in 26 families (26/72 (36.1%)), while negative pES results or identification of VUS encouraged 40 families (40/72 (55.6%)) to continue their pregnancy, which ended in a live birth in all cases.
CONCLUSION: Trio-based pES can provide additional genetic information for pregnancies with fetal ultrasound anomalies without a CNV-seq diagnosis. The incidental findings and parental carrier status reported by trio-based pES with splice-site and mitochondrial genome analysis extend its clinical application, but careful genetic counseling is warranted. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Zhu X, Gao Z, Wang Y, et al. Utility of trio-based prenatal exome sequencing incorporating splice-site and mitochondrial genome assessment in pregnancies with fetal ultrasound anomalies: prospective cohort study. Ultrasound Obstet Gynecol. 2022. PMID: 35726512. doi:10.1002/uog.24974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。